Tuesday, September 02, 2014

Dr. Bill Quick's Posts

CGM and Medicare

CGM (continuous glucose monitoring) has become a well-accepted, although expensive, component of diabetes care. It's particularly helpful for people on insulin, who risk hypoglycemia or hyperglycemia if there's a mismatch between their insulin dose and food or activity levels. Commercially-available CGM devices consist of an embedded sensor that... Read moreChevron

Another Antibody Test for Type 1 Diabetes

The FDA has just approved a new antibody test to help diagnose type 1 diabetes. It is a laboratory-based test, not an at-home test, and will be available for US and Canadian labs to use in the near future. The test has nothing to do with glucose levels or A1Cs, but instead is a marker for antibodies relating to T1D -- which is an autoimmune... Read moreChevron

A Tale of Two Insulins and a Lot of Lawyers

I read recently about two insulins where the lawyering has gotten pretty intense. One is the sad tale of a me-too insulin that just got approved in the United States, but can't be sold here, and the other is an insulin delivery system that's not approved in the U.S., but which you apparently can buy in Equador, Algeria, and Lebanon. And previously... Read moreChevron

Plant-based Meal Plans May Help Diabetic Neuropathy

A recent presentation at the AADE meeting suggests that a combination of a plant-based diet plus vitamin B12 may help a common form of painful diabetic neuropathy called distal symmetric polyneuropathy (DPN).   DPN is common in people with diabetes, and is usually attributed to long-term poor diabetes control – but it may also... Read moreChevron

Back to the Drawing Board

  Otelixizumab is one of those drugs whose names are tongue-twisters that seem invented by someone's computer-name-generating program. Sometimes known as TRX4, it's a monoclonal antibody, and is being developed for treatment of type 1a (autoimmune) diabetes and possibly for other autoimmune diseases. Biologics in this class have been... Read moreChevron